Nicholas Investment Partners LP Decreases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Nicholas Investment Partners LP decreased its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 9.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 157,635 shares of the company’s stock after selling 16,110 shares during the period. Nicholas Investment Partners LP’s holdings in Enliven Therapeutics were worth $3,547,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after acquiring an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at approximately $97,000. BNP Paribas Financial Markets purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at approximately $112,000. ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at approximately $200,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth approximately $228,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the business’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the completion of the transaction, the insider now directly owns 997,688 shares of the company’s stock, valued at approximately $16,032,846.16. The trade was a 0.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $18.39, for a total value of $122,606.13. Following the completion of the sale, the chief operating officer now owns 309,976 shares of the company’s stock, valued at approximately $5,700,458.64. The trade was a 2.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,111 shares of company stock worth $1,493,145. 29.20% of the stock is owned by corporate insiders.

Enliven Therapeutics Trading Up 5.4%

NASDAQ:ELVN opened at $20.03 on Wednesday. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.03. The business’s fifty day moving average price is $18.99 and its 200 day moving average price is $21.91. The firm has a market capitalization of $982.79 million, a price-to-earnings ratio of -10.54 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. Equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.